Show simple item record

dc.contributor.authorJanssens, B
dc.contributor.authorVan Herp, M
dc.contributor.authorGoubert, L
dc.contributor.authorChan, S
dc.contributor.authorUong, S
dc.contributor.authorNong, S
dc.contributor.authorSocheat, D
dc.contributor.authorBrockman, A
dc.contributor.authorAshley, E A
dc.contributor.authorVan Damme, W
dc.date.accessioned2008-02-07T16:56:24Z
dc.date.available2008-02-07T16:56:24Z
dc.date.issued2007-02
dc.identifier.citationA randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia. 2007, 12 (2):251-9 Trop. Med. Int. Healthen
dc.identifier.issn1360-2276
dc.identifier.pmid17300633
dc.identifier.doi10.1111/j.1365-3156.2006.01786.x
dc.identifier.urihttp://hdl.handle.net/10144/17743
dc.description.abstractOBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in Cambodia.
dc.language.isoenen
dc.publisherWiley-Blackwell
dc.relation.urlhttp://www.blackwell-synergy.com/loi/tmi
dc.rightsArchived on this site with the kind permission of Wiley-Blackwellen
dc.subject.meshAdolescenten
dc.subject.meshAdulten
dc.subject.meshAgeden
dc.subject.meshAnemiaen
dc.subject.meshAntimalarialsen
dc.subject.meshArtemisininsen
dc.subject.meshCambodiaen
dc.subject.meshChilden
dc.subject.meshChild, Preschoolen
dc.subject.meshDrug Therapy, Combinationen
dc.subject.meshFemaleen
dc.subject.meshGenome, Protozoanen
dc.subject.meshHumansen
dc.subject.meshInfanten
dc.subject.meshMalaria, Falciparumen
dc.subject.meshMalaria, Vivaxen
dc.subject.meshMaleen
dc.subject.meshMefloquineen
dc.subject.meshMiddle Ageden
dc.subject.meshQuinolinesen
dc.subject.meshRecurrenceen
dc.subject.meshSesquiterpenesen
dc.subject.meshTreatment Outcomeen
dc.titleA randomized open study to assess the efficacy and tolerability of dihydroartemisinin-piperaquine for the treatment of uncomplicated falciparum malaria in Cambodia.en
dc.contributor.departmentMédecins Sans Frontières, Phnom Penh, Cambodia. b.janssens@bigfoot.comen
dc.identifier.journalTropical Medicine & International Healthen
refterms.dateFOA2019-03-04T09:13:10Z
html.description.abstractOBJECTIVES: To compare the efficacy and tolerability of dihydroartemisinin-piperaquine (DHA-PQP) with that of a 3-day regimen of mefloquine and artesunate (MAS3) for the treatment of uncomplicated falciparum malaria in Cambodia. METHOD: Randomized open-label non-inferiority study over 64 days. RESULTS: Four hundred and sixty-four patients were included in the study. The polymerase chain reaction genotyping-adjusted cure rates on day 63 were 97.5% (95% confidence interval, CI, 93.8-99.3) for DHA-PQP and 97.5% (95% CI, 93.8-99.3) for MAS3, P = 1. There were no serious adverse events, but significantly more episodes of vomiting (P = 0.03), dizziness (P = 0.002), palpitations (P = 0.04), and sleep disorders (P = 0.03) reported in the MAS3 treatment group, consistent with the side-effect profile of mefloquine. CONCLUSIONS: DHA-PQP was as efficacious as MAS3, but much better tolerated, making it more appropriate for use in a routine programme setting. This highly efficacious, safe and more affordable fixed-dose combination could become the treatment of choice for Plasmodium falciparum malaria in Cambodia.


Files in this item

Thumbnail
Name:
Janssens Cambodia[1].pdf
Size:
644.3Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record